New insights into melanoma tumor metabolism reveal metabolic reprogramming as a significant barrier to effective immunotherapy. Complex interactions within the tumor microenvironment inhibit immune responses, underpinning resistance to current treatments. These findings, published recently, identify metabolic pathways that tumors exploit to evade immune surveillance, providing potential targets to enhance immunotherapy efficacy in melanoma patients.